10 Best Stocks To Invest In According to Billionaires

6. Danaher Corporation (NYSE:DHR)

Number of Billionaire Investors: 25

Danaher Corporation (NYSE:DHR) is a global leader in science and technology, specializing in Biotechnology, Life Sciences, and Diagnostics. The company provides bioprocessing technologies, lab equipment, and diagnostic tools to improve human health.

On September 6, TD Cowen reiterated its Buy rating on Danaher Corporation (NYSE:DHR), setting a price target of $310. This came after an investor day focused on diagnostics, where the company highlighted a strategic shift towards platform-level innovation rather than an Operating Company (OpCo) approach.

Danaher Corporation (NYSE:DHR) reaffirmed its financial guidance for Q3 and the full year of 2024, despite projecting a slight year-over-year decline in non-GAAP core revenue. In Q2, the company exceeded expectations with $5.7 billion in revenue, driven by strategic acquisitions and its focus on biotech and life sciences. Additionally, Cepheid’s 4-in-1 diagnostic tests for COVID-19, Flu A and B, and RSV are expected to boost future revenue.

According to Insider Monkey, 25 billionaires, including Ken Fisher and Israel Englander, held stakes in Danaher Corporation (NYSE:DHR).

RGA Investment Advisors stated the following regarding Danaher Corporation (NYSE:DHR) in its first quarter 2024 investor letter:

“In our Q3 2023 commentary, we featured a section on our investment in Danaher Corporation (NYSE:DHR) entitled “Purity in the Crown Jewel of Bioprocessing.” Specifically, we were speaking to Cytiva, Danaher’s bioprocessing business formed by the merger of Pall Corp and GE’s bioprocessing division. We will not repeat the features that attract us to bioprocessing in general, nor the elements of timeliness, though we will emphasize that our confidence in timeliness has actually increased since writing that piece. While Danaher has performed admirably ever since, its peer Sartorius, which was referenced by labeling bioprocessing “an oligopolistic market, with a small number of critical players and extremely high barriers to entry.”